Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07227428
PHASE4

Comparison of Glucocorticoid Tapering Schedules in Rheumatoid Arthritis

Sponsor: Seoul National University Hospital

View on ClinicalTrials.gov

Summary

This multicenter, randomized, controlled, single-blind prospective study aims to establish an evidence-based protocol for discontinuing long-term low-dose glucocorticoids in patients with rheumatoid arthritis (RA). The study will compare two tapering strategies (1) a split-dose tapering method, in which the 5 mg tablet is divided into halves and gradually reduced, and (2) a sequential 1 mg-by-1 mg tapering method. A total of 206 patients (including 50 from Seoul National University Hospital) will be enrolled and followed for six months. Participants will be randomly assigned to one of the two tapering arms, and an exploratory group will include patients who continue low-dose prednisolone without tapering. The primary efficacy endpoint is the change in RA disease activity, measured by DAS28-CRP, to demonstrate non-inferiority between the two tapering strategies. Secondary endpoints include the success rate of glucocorticoid discontinuation and changes in disease activity over time. This trial seeks to define a standardized, practical glucocorticoid tapering protocol tailored to Korean RA patients. The findings are expected to support safer steroid withdrawal, reduce treatment-related adverse events, and guide clinical decision-making in long-term management of rheumatoid arthritis.

Official title: Comparison of Glucocorticoid Tapering Schedules in Rheumatoid Arthritis.

Key Details

Gender

All

Age Range

19 Years - Any

Study Type

INTERVENTIONAL

Enrollment

206

Start Date

2025-12-01

Completion Date

2027-12-31

Last Updated

2025-11-25

Healthy Volunteers

No

Interventions

DRUG

Prednisolone

PD will be tapered using a 5mg tab formulation

DRUG

Prednisolone

PD will be tapered using a 1 mg tab formulation

DRUG

Prednisolone

PD will be continued